ANTIMICROBIAL AND/OR EPITHELIAL CELL GROWTH STIMULATING SUBSTANCE AND COMPOSITION AND TISSUE DRESSING MATERIAL
A chitosan for use in an antimicrobial treatment of a patient's tissue and a pharmaceutical composition comprising a chitosan for use in an antimicrobial treatment of a patient's tissue. A method of treating a microbial infection, the method comprising the step of administering to a patient an effective amount of a chitosan and an aqueous solution comprising chitosan. A chitosan or a pharmaceutical composition comprising a chitosan for use in an epithelial cell growth stimulating treatment of a patient's tissue. A method of stimulating the growth of epithelial cells the method comprising the step of administering to a patient or to an epithelial cells containing cell culture an effective amount of a chitosan or a pharmaceutical composition comprising chitosan. A tissue dressing material characterized in that it consists of chitosan or a chitosan comprising composition.
1 . A method for treating a microbial infection, preventing the risk of a microbial infection, reducing the microbial load of an existing microbial infection, or preventing or reducing the spread of a microbial infection, with methicillin-resistant Staphylococcus aureus (MRSA) infection, oxacillin-resistant Staphylococcus aureus (ORSA) infection, multidrug-resistant Clostridium difficile infection, penicillin-resistant Streptococcus pneumonia infection, multidrug-resistant Pseudomonas aeruginosa infection, or multidrug-resistant Acinetobacter baumannii infection, the method comprising:
administering to a patient an effective amount of a native chitosan or a pharmaceutical composition comprising native chitosan.
2 . The chitosan method according to claim 1 , wherein
the treatment is locally confined.
3 . The chitosan method according to claim 1 , wherein
the chitosan's degree of acetylation is 40% or less.
4 . The method according to claim 3 , wherein
the chitosan is deacetylated.
5 . The method according to claim 3 , wherein
the chitosan is preparable by a method that comprises at least two deacetylation steps.
6 . The method according to claim 1 , wherein
a fraction of more than 10% of the chitosan is present in a form that is insoluble at a pH of 6.5 or greater.
7 . The method according to claim 1 , wherein
a fraction of more than 1% of the chitosan is present in a form that is soluble at a pH of 6.5.
8 . The method according to claim 1 , wherein
a fraction of more than 10% of the chitosan has a molecular weight of 10 kD or more.
9 . The method according to claim 1 , wherein
a fraction of more than 0.1% of the chitosan has a molecular weight of less than 10 kD.
10 . A pharmaceutical composition for for treating a patient's tissue for at least one of the following or a combination thereof: preventing the risk of a microbial infection, reducing the microbial load of an existing microbial infection, preventing or reducing the spread of a microbial infection, the infection is at least one of the following or a combination thereof: methicillin-resistant Staphylococcus aureus (MRSA) infection, oxacillin-resistant Staphylococcus aureus (ORSA) infection, multidrug-resistant Clostridium difficile infection, penicillin-resistant Streptococcus pneumonia infection, multidrug-resistant Pseudomonas aeruginosa infection, multidrug-resistant Acinetobacter baumannii infection, the pharmaceutical composition comprising a native chitosan.
11 . The pharmaceutical composition according to claim 10 , wherein
the pharmaceutical composition is free of alcohol.
12 . The pharmaceutical composition according to claim 10 , wherein
the pharmaceutical composition is a liquid.
13 . The pharmaceutical composition according to claim 12 , wherein
the pharmaceutical composition is an aqueous solution of chitosan.
14 . The pharmaceutical composition according to claim 10 , wherein
the pharmaceutical composition is solid or gel-like.
15 . The pharmaceutical composition according to claim 10 , wherein
the treatment is locally confined.
16 - 18 . (canceled)
19 . A method of stimulating the growth of epithelial cells the method comprising: administering to a patient or to an epithelial cells containing cell culture an effective amount of native chitosan or a pharmaceutical composition comprising native chitosan.
20 . The method of claim 20 , wherein
the epithelial cells are keratinocytes.
21 . A method of preparing chitosan for use in an antimicrobial treatment of a patient's tissue or in an epithelial cell growth stimulating treatment, wherein
the chitosan is deacetylated in at least two deacetylation steps.
22 . A tissue dressing material consisting of chitosan with a degree of acetylation of 20% or less, wherein
a fraction of more than 10% of the chitosan has a molecular weight of 10 kD or more and a fraction of more than 0.1% of the chitosan has a molecular weight of less than 10 kD.
23 . The tissue dressing material of claim 22 , wherein
the chitosan is native chitosan.
24 . The tissue dressing material according to claim 23 , wherein
the chitosan is deacetylated.
25 . The tissue dressing material according to claim 22 , wherein
the chitosan is preparable by a method that comprises at least two deacetylation steps.
26 . The tissue dressing material according to claim 22 , wherein
a fraction of more than 10% of the chitosan is present in a form that is insoluble at a pH of 6.5 or greater.
27 . The tissue dressing material according to claim 22 , wherein
a fraction of more than 1% of the chitosan is present in a form that is soluble at a pH of 6.5.
28 . A tissue dressing material being a composition comprising chitosan with a degree of acetylation of 20% or less, wherein
a fraction of more than 10% of the chitosan has a molecular weight of 10 kD or more and
a fraction of more than 0.1% of the chitosan has a molecular weight of less than 10 kD.
29 . The tissue dressing material according to claim 28 , wherein
the chitosan containing composition is free of alcohol or any other organic solubilizer or stabilizer.
30 . The tissue dressing material according to claim 28 , wherein
the chitosan containing composition is a liquid.
31 . The tissue dressing material according to claim 30 , wherein
the chitosan containing composition is an aqueous solution of chitosan.
32 . The tissue dressing material according to claim 28 , wherein
the chitosan containing composition is solid or gel-like.
33 . An aqueous solution comprising chitosan with a degree of acetylation of 20% or less, wherein
a fraction of more than 10% of the chitosan has a molecular weight of 10 kD or more and
a fraction of more than 0.1% of the chitosan has a molecular weight of less than 10 kD.
34 . The pharmaceutical composition of claim 10 wherein the chitosan's degree of acetylation is 40% or less or wherein the chitosan is deacetylated.
35 . The pharmaceutical composition of claim 10 wherein the chitosan is preparable by a method that comprises at least two deacetylation steps.
36 . The pharmaceutical composition of claim 10 wherein a fraction of more than 10% of the chitosan is present in a form that is insoluble at a pH of 6.5 or greater or wherein a fraction of more than 1% of the chitosan is present in a form that is soluble at a pH of 6.5.
37 . The pharmaceutical composition of claim 10 wherein a fraction of more than 10% of the chitosan has a molecular weight of 10 kD or more or wherein a fraction of more than 0.1% of the chitosan has a molecular weight of less than 10 kD.